Schwilden H
Friedrich-Alexander-Universität Erlangen-Nürnberg, Klinik für Anästhesiologie.
Arzneimittelforschung. 1997 Oct;47(10):1172-3.
During the past three decades anaesthesia-related mortality has been reduced to an extent which is more or less exclusively governed by human error. This improvement has been achieved by nearly equal progresses in drug development as well as in the development of technical devices, especially in monitoring. Nearly 80% of all anaesthetics which are used today in an anaesthetic university department were developed in the last 30 years. The search and research for better controllable compounds has caused the necessity to develop also devices which are able to deliver these substances continuously. One might therefore reason that the term pharmaceutical which today is entirely based on the term compound has in the future to be based on a combination of compound and device. The pharmacist of today and yesterday may in the future become a high-tech microsystems engineer. From an academic point of view it is unsatisfactory that the degree of therapeutic success can only be achieved and documented very incompletely. Partially this is due to the fact that the anaesthesiologists are not able to formulate their therapeutic goals, stating which higher integrative brain functions have to be reduced to what degree to guarantee an optimum therapeutic level.
在过去三十年中,与麻醉相关的死亡率已降低到或多或少完全由人为失误决定的程度。这一改善是通过药物研发以及技术设备(尤其是监测设备)的发展取得的几乎同等进展实现的。如今在大学麻醉科使用的所有麻醉剂中,近80%是在过去30年中研发出来的。对更好控制的化合物的探索和研究导致了开发能够持续输送这些物质的设备的必要性。因此,人们可能会推断,如今完全基于化合物一词的“药物”一词在未来将基于化合物和设备的组合。今天和过去的药剂师未来可能会成为高科技微系统工程师。从学术角度来看,治疗成功的程度只能非常不完整地实现和记录,这是不能令人满意的。部分原因在于麻醉医生无法明确表述他们的治疗目标,即必须将哪些高级整合脑功能降低到何种程度才能保证达到最佳治疗水平。